Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Cassiopea","sponsor":"Cosmo Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cassiopea Receives FDA Approval for Winlevi\u00ae (clascoterone Cream 1%)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"ITALY","productType":"Small molecule","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Cassiopea"},{"company":"Cassiopea","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","amount":"$235.0 million","upfrontCash":"$45.0 million","newsHeadline":"Sun Pharma, Cassiopea Signing of License and Supply Agreements for Winlevi\u00ae","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"ITALY","productType":"Small molecule","productStatus":"Approved","date":"July 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Cassiopea"},{"company":"Cassiopea","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$7.0 million","newsHeadline":"Cosmo and Sun Pharma Announce Territory Expansion of License and Supply Agreements for WINLEVI\u00ae to include Japan, Australia, New Zealand, Brazil, Mexico and Russia","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"ITALY","productType":"Small molecule","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Cassiopea"}]

Cassiopea

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Cosmo and Sun Pharma Announce Territory Expansion of License and Supply Agreements for WINLEVI® to include Japan, Australia, New Zealand, Brazil, Mexico and Russia

Details:

Under the terms of the above referred agreements, Sun Pharma will receive from Cassiopea the exclusive right to develop and commercialize WINLEVI (clascoterone) in Japan, Australia, New Zealand, Brazil, Mexico and Russia.

Lead Product(s): Clascoterone

Therapeutic Area: Dermatology Product Name: Winlevi

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Sun Pharmaceutical Industries Limited

Deal Size: Undisclosed Upfront Cash: $7.0 million

Deal Type: Licensing Agreement July 25, 2022

ASK
US

Upload
your Pipeline Activity

Cassiopea

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Sun Pharma, Cassiopea Signing of License and Supply Agreements for Winlevi®

Details:

Under the terms of the above referred agreements, Sun Pharma will have the exclusive right to commercialize Winlevi® in the United States and Canada, and Cassiopea will be the exclusive supplier of the product.

Lead Product(s): Clascoterone

Therapeutic Area: Dermatology Product Name: Winlevi

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Sun Pharmaceutical Industries Limited

Deal Size: $235.0 million Upfront Cash: $45.0 million

Deal Type: Licensing Agreement July 26, 2021

ASK
US

Upload
your Pipeline Activity

Cassiopea

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Cassiopea Receives FDA Approval for Winlevi® (clascoterone Cream 1%)

Details:

Winlevi (clascoterone cream 1%) is approved for the treatment of acne vulgaris in people aged 12 and older. In pivotal clinical trials, WINLEVI demonstrated treatment success and reductions in acne lesions and was well tolerated when used twice a day.

Lead Product(s): Clascoterone

Therapeutic Area: Dermatology Product Name: Winlevi

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Cosmo Pharmaceuticals

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 27, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY